Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Shi

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialScott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
Circulation. Heart Failure|January 13, 2016
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyMichael R Zile, Pardeep S Jhund, Catalin F Baicu, et al.
European Journal of Heart Failure|January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HFMaria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
Journal of the American College of Cardiology|July 16, 2016
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure HospitalizationAkshay S Desai, Brian L Claggett, Milton Packer, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
JAMA Cardiology|December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialLuis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
Lancet (London, England)|February 23, 2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris, Pantelis A Sarafidis, Matthew R Weir, et al.
Blood Pressure|April 25, 2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular riskMichael A Weber, George L Bakris, Björn Dahlöf, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialScott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
Circulation. Heart Failure|January 13, 2016
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyMichael R Zile, Pardeep S Jhund, Catalin F Baicu, et al.
European Journal of Heart Failure|January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HFMaria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
Journal of the American College of Cardiology|July 16, 2016
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure HospitalizationAkshay S Desai, Brian L Claggett, Milton Packer, et al.
Journal of the American College of Cardiology|March 9, 2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian Claggett, et al.
JAMA Cardiology|December 8, 2022
Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialLuis E Rohde, André Zimerman, Muthiah Vaduganathan, et al.
Lancet (London, England)|February 23, 2010
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris, Pantelis A Sarafidis, Matthew R Weir, et al.
Blood Pressure|April 25, 2007
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular riskMichael A Weber, George L Bakris, Björn Dahlöf, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
Pageof 7